Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | Chief Development Officer | February 13, 2020 | February 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Trevi Therapeutics, Inc.
Report date February 13, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2030-02-12 | Direct | 30,000 |
Reported balance
After 2020-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-13 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted on February 13, 2020. The 30,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 13, 2020. The 30,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2020 Filed Feb 18, 2020 21:24 UTC | Trevi Therapeutics, Inc. TRVI · Entity 4387 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004881 · doc4.xml · derivative · entry 1 Brett-Smith Helena · CIK 0001774731 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: This option was granted on February 13, 2020. The 30,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.